Initial experience with ablation of ventricular arrhythmias using a pulsed-field system

Abstract

Abstract Introduction Catheter ablation using radiofrequency (RF) current is a well-established method of treatment of ventricular arrhythmias (VA). However, RF ablation may fail to eliminate deeply located arrhythmogenic substrate. Pulsed-field (PF) is a novel energy source with a potential to create deeper lesions, especially in scar tissue. Purpose This study aims to present the data on safety and efficacy (acute outcome data) of VA ablation using PF. Methods The population consists of 15patients (5 women, age: 61 ± 19years) after previously failed RF ablation of VA. The underlying condition was nonischemic cardiomyopathy (53%), coronary artery disease (13%), and congenital heart disease (13%), respectively. No structural heart disease was present in 20% of cases. The mean left ventricular ejection fraction was 39 ± 13%. Eighty percent of patients had sustained VA, the remaining patients presented with frequent ventricular ectopy. Ablation was performed using a conventional irrigated 4-mm tip catheter in a combination with commercially available PF generator. Peripheral venous blood samples for the assessment of the plasmatic levels of high-sensitivity troponin T (hsTnT) were obtained the next day (usually 18-24hours) after the procedure. Results A mean of 17±12 PF applications (25A) per patient were delivered. In 5 patients (33%), an additional RF ablation (4±9 applications) was performed. Acute success as assessed by non-inducibility of VA or elimination of ectopic focus was achieved in all but one patient (93%). In 4 cases (27%), PF energy was applied within the great cardiac vein and subsequent coronary angiography did not reveal any abnormality. On the other hand, transient conduction system block occurred in 3 cases (20%) during PF application on the lateral LV wall remotely from the LV septum (complete AV block in one, LBBB in two patients). These events resolved in all cases within one hour. Ablation using PF did not result in excessive increase of hsTnT (657±482ng/l, with upper reference level of 14ng/l). Conclusion Initial experience with PF for the treatment of VA indicates high acute efficacy. The long-term effect is to be determined. PF applications in the ventricle may be associated with unexpected but transient conduction system damage, even when applications are performed remotely from the interventricular septum. The postprocedural increase in plasma troponin levels is only moderate.